Gene test may cut chemo harm in pancreatic and colon cancer
NCT ID NCT05391126
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether using a person's genetic information to guide chemotherapy dosing can lower the risk of severe side effects. About 178 adults with colorectal or pancreatic cancer will be randomly assigned to either standard dosing or dosing based on their UGT1A1 gene type. The main goal is to see if the gene-guided approach reduces serious side effects during the first treatment cycle.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Kentucky
RECRUITINGLexington, Kentucky, 40506, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Your gut bacteria might reveal hidden cancer risk
- Can a smart digital program restore sleep for cancer survivors?
- Can a new infusion drug shrink Hard-to-Treat tumors?